Creative Medical Technology Holdings (CELZ) EBT Margin (2017 - 2025)
Creative Medical Technology Holdings' (CELZ) quarterly EBT Margin came in at 62922.47% in Q4 2025, down 112000.0% year-over-year from N/an in Q4 2024, and down 15.24% quarter-over-quarter from 54603.23% in Q1 2025.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) EBT Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported EBT Margin for 9 consecutive years, with 62922.47% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBT Margin fell 112000.0% year-over-year to 62922.47% in Q4 2025; TTM through Jun 2026 was 201285.83%, a 10519235.0% decrease from a year earlier, with the FY2025 full-year figure at 99916.8%, down 4997606.0% from the prior year.
- EBT Margin was 62922.47% for Q4 2025 at Creative Medical Technology Holdings, down from 54603.23% in the prior quarter.
- Over five years, EBT Margin peaked at 1786.07% in Q3 2022 and troughed at 62922.47% in Q4 2025.
- A 5-year average of 31257.95% and a median of 26642.18% in 2021 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin soared 21496579 bps in 2021 and tumbled 2769778 bps in 2022, its largest moves.
- Over 5 years, EBT Margin stood at 5719.92% in 2021, then tumbled by 484 bps to 33417.7% in 2022, then sank by 67 bps to 55952.47% in 2023, then fell by 10 bps to 61802.47% in 2024, then declined by 2 bps to 62922.47% in 2025.
- The last three EBT Margin figures came in at 62922.47% (Q4 2025), 54603.23% (Q1 2025), and 61802.47% (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -24,299.18% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | Creative Medical Technology Holdings | 1.45 Mn | 1.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -62,922.47% |
| Mar 31, 2025 | -54,603.23% |
| Dec 31, 2024 | -61,802.47% |
| Jun 30, 2024 | -19,471.60% |
| Dec 31, 2023 | -55,952.47% |
| Sep 30, 2023 | -24,232.53% |
| Dec 31, 2022 | -33,417.70% |
| Sep 30, 2022 | -1,786.07% |
| Mar 31, 2022 | -7,699.13% |
| Dec 31, 2021 | -5,719.92% |
| Sep 30, 2021 | -18,435.96% |
| Jun 30, 2021 | -29,051.82% |
| Dec 31, 2020 | -220,685.70% |
| Sep 30, 2020 | 512.79% |
| Jun 30, 2020 | -6,604.17% |
| Mar 31, 2020 | 8,889.50% |
| Dec 31, 2019 | 117,998.86% |
| Sep 30, 2019 | -4,184.56% |
| Jun 30, 2019 | -143.24% |
| Mar 31, 2019 | -1,569.62% |